Introduction: This study examined the difference in overall survival (OS) between peritoneal metastatic gastric cancer (PMGC) patients who underwent neoadjuvant chemotherapy followed by cytoreductive surgery ± hyperthermic intraperitoneal chemotherapy (CRS ± HIPEC) and those who did not have surgery but instead received palliative chemotherapy. Methods: This retrospective study included 80 patients who were followed up with the diagnosis of PMGC, those undergoing neoadjuvant chemotherapy followed by CRS ± HIPEC (CRS ± HIPEC group) and those receiving chemotherapy only (non-surgical group), in the medical oncology clinic between April 2011 and December 2021. Clinicopathological features, treatments, and OS of the patients were compared. Results: There were 32 patients in the SRC CRS ± HIPEC group and 48 in the non-surgical group. In the CRS ± HIPEC group, CRS + HIPEC was performed on 20 patients, and only CRS was performed on 12 patients. All of the patients who underwent CRS + HIPEC, and 5 of the patients who underwent only CRS received neoadjuvant chemotherapy. While the median OS was 19.7 (15.5–23.8) months in the CRS ± HIPEC group, the median OS was 6.8 (3.5–10.2) months in the non-surgical group (p < 0.001). Conclusion: As a result, CRS + HIPEC significantly improves survival in PMGC patients. With experienced surgical centres and appropriate patient selection, the life expectancy of patients with PM can be extended.

In our study, we determined the changes in the oxidative stress (OxS) biomarkers, thiol-disulfide (TD) homeostasis and ischemia-modified albumin (IMA) levels, in patients diagnosed with ovarian carcinoma before and after chemotherapy. We will examine the indirect effects of chemotherapy on OxS and antioxidant capacity by measuring changes in these blood biomarkers and compare the results with those of the healthy control group. This case–control study, which was conducted in a single-center, prospective design, included 42 patients diagnosed with ovarian cancer and 51 healthy volunteers. Venous blood samples were taken from all participants after 8 h of fasting, their serum was separated, and the serum total thiol, native thiol, disulfide, and IMA values were measured. In the comparison of the blood samples taken before the chemotherapy treatment of the patient group with the healthy control group, the native thiol (p < 0.001), total thiol (p < 0.001), and native thiol/total thiol (p < 0.001) values were found to be statistically significantly lower, and the disulfide (p = 0.001), disulfide/native (p < 0.001), and disulfide/total thiol (p < 0.001) levels were found to be statistically significantly greater. In the patient group diagnosed with ovarian cancer, a statistically significant difference was detected between the measurements of cancer antigen-125 (CA-125) (p < 0.001), native thiol (p = 0.019), and total thiol (p = 0.025) values at the 0th month before chemotherapy treatment and the third month after chemotherapy treatment. In the group that received adjuvant chemotherapy after the operation, the native thiol (p = 0.035), total thiol (p = 0.043), disulfide/native thiol (p = 0.035), disulfide total thiol (p = 0.035), native thiol/total thiol (p = 0.035) and IMA (p = 0.026) values were statistically significantly different between the diagnosis and third-month values. Our study suggests that TD homeostasis may be an important guide in terms of disease progression, complications during chemotherapy treatment, appropriate dose reductions, and modifications in chemotherapy depending on the toxicities experienced and the goals of the treatment.

Colon lymphoma is a rare type of gastrointestinal lymphoma and represents 0.2% to –1.2% of all primary colon cancers. This study aimed to retrospectively examine the general characteristics, treatment methods, and survival characteristics of patients with colon lymphoma who were followed-up at our center. This retrospective study included patients diagnosed with colon lymphoma who were followed up at Ankara Numune Training and Research Hospital and Ankara Bilkent City Hospital between December 2005 and June 2023. Clinicopathological features, radiological findings, treatments, and modalities of patients were obtained from their medical records. Fourteen patients with primary colon lymphoma were included in the study. Thirteen patients (92.9%) were diagnosed with diffuse large B-cell lymphoma. The median age of the patients was 55 (28–84) years. The tumor location was the terminal ileum/cecum in 50% of the patients. At the time of diagnosis, 10 patients (7 with stage 1E-2E disease, 2 with stage 3E disease, and 1 with stage 4E disease due to tumor obstruction) underwent surgery. Twelve patients received chemotherapy (6 patients as adjuvant and 6 patients as first-line treatment). The median overall survival (OS) was 10 years (0.1–21.5) years, the 5-year median OS was 71%, and the 10-year median OS was 53%. Primary colon lymphoma is a rare disease and its optimal treatment is not clearly defined. The primary treatment for primary colon lymphoma is a combination of surgery and chemotherapy. A clear consensus on the treatment can be established through prospective studies.

Background: COVID 19 continues to affect the whole world with its different presentations and unenlightened aspects.Older patients are the group most at risk. Low hemoglobin levels contribute to hypoxia during COVID 19 infection and increase the risk of complications, especially in risky groups. In this study, we aimed to investigate the prevalence of anemia and its effect on mortality in geriatric COVID 19 patients. Materials and Methods: Data of 251 patients over the age of 65 who were followed up in the Internal Medicine services allocated for COVID 19 of our hospital between August and October 2020, were included in the study. Anemia was defined as a hemoglobin level of 13 mg/dl in men and below 12 mg/dl in women at the time of admission. Demographic and laboratory data of the patients and hemoglobin levels were compared. Results: The mean age of 251 COVID-19 patients included in the study was 75.6±7.6 years. 45.8% (n:115) of the patients were female and 54.2% (n:136). While 51.8% of the patients had anemia, the presence of anemia was found to be 67.9% in patients who died due to COVID 19. According to multivariate logistic regression analysis, advanced age (OR=1.082; 95% CI=1.03-1.137; p=0.002), presence of anemia (OR=1.969; 95% CI=1.113-4.246; p=0.034),hypertension (OR =5.763; 95% CI=1.713-19.389; p=0.005), dementia (OR=3.614; 95% CI=1.128-11.578; p=0.031) were determined as independent risk factors predicting mortality in patients with COVID-19. Conclusion: Advance age, presence of anemia, hypertension and dementia has been found as İndependant risk factors for mortality in COVID 19 infection in our study. In elderly Covid 19 patients hemoglobin levels at admission may be helpful in predicting mortality.

Background/Objective: Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive malignancy with limited therapeutic options and poor survival outcomes. Recent advances in molecular oncology have highlighted the significance of isocitrate dehydrogenase 1 (IDH1) mutations as potential therapeutic targets. However, data on the prevalence and prognostic implications of IDH1 mutations in patients with iCCA are scarce. This study aimed to retrospectively investigate the IDH1 mutation rate, histopathological features, and survival outcomes of patients with iCCA. Methods: We retrospectively analyzed 88 patients diagnosed and treated between 2005 and 2025 at two tertiary oncology centers. Clinical, pathological, and survival data were obtained from the institutional oncology archives and national population databases. IDH1 mutation status was evaluated using polymerase chain reaction and next-generation sequencing of paraffin-embedded tissue samples. Results: A total of 88 patients with iCCA were included, with a median age of 62 years, and 62.5% were male. Abdominal pain was the most common presenting symptom (67%). The most frequent stages at diagnosis were stage IB and stage IIIB (22.7% each). Histopathologically, the small-duct subtype (55.7%), nodular morphology (67.0%), and solitary tumors (79.5%) predominated. IDH1 mutation was detected in 2.3% of patients. Curative surgery was performed in 78.2% of cases and was more common in early-stage disease. Gemcitabine–capecitabine was the most frequently used adjuvant regimen, whereas gemcitabine–cisplatin was the most common palliative treatment regimen. Median overall survival differed significantly by albumin-bilirubin (ALBI) grade, with 40.1, 11.1, and 4.4 months for grades 1, 2, and 3, respectively (p < 0.001). Conclusions: In this multicenter cohort, iCCA was characterized by diverse clinicopathological features and treatment approaches. Surgical resection remains the main treatment modality for patients with localized disease, whereas systemic therapies are more frequently used in advanced stages. The findings highlight the prognostic relevance of baseline clinical and biochemical characteristics and may improve risk stratification in patients with iCCA.